Jul 15, 2019
Aquestive Therapeutics Completes $70 Million Debt Refinancing
Jun 04, 2019
Aquestive Therapeutics Completes Enrollment in Libervant(TM) (diazepam buccal film) Crossover Study
May 08, 2019
Aquestive Therapeutics Reports First Quarter 2019 Financial Results and Recent Business Highlights
Apr 16, 2019
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application for Riluzole Oral Film for Treatment of ALS
Mar 25, 2019
Aquestive Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Mar 14, 2019
Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights
Mar 07, 2019
Aquestive Therapeutics to Present at Oppenheimer's 29th Annual Healthcare Conference
Feb 08, 2019
Aquestive Therapeutics to Present at 2019 BIO CEO & Investor Conference
Jan 31, 2019
Aquestive Therapeutics Provides Update on Licensee, Sunovion Pharmaceuticals Inc.'s Apomorphine Sublingual Film (APL-130277) New Drug Application
Jan 25, 2019
Aquestive Therapeutics Granted Temporary Restraining Order (TRO) Against Alvogen
Jan 03, 2019
Aquestive Therapeutics Appoints Gary H. Slatko, M.D. as Chief Medical Officer
Dec 20, 2018
Aquestive Therapeutics Provides End of Year Business Update, Including Progress of its Proprietary CNS Assets, Financial and Legal Matters
Dec 18, 2018
Aquestive Therapeutics Schedules Business Update Conference Call on December 20, 2018
Dec 07, 2018
Aquestive Therapeutics to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Dec 03, 2018
Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
Nov 29, 2018
Aquestive Therapeutics Launches SYMPAZAN(TM) (clobazam) Oral Film with Widespread U.S. Availability
Nov 16, 2018
Aquestive Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration (FDA) for Tadalafil Oral Film
Nov 06, 2018
Aquestive Therapeutics Reports Third Quarter 2018 Financial Results and Recent Business Highlights
Nov 02, 2018
Aquestive Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval for SYMPAZAN(TM) (clobazam) Oral Film
Oct 25, 2018
Aquestive Therapeutics to Announce Third Quarter 2018 Financial Results and Recent Business Highlights on November 6, 2018